Experts Debate Optimal Approaches to the Treatment of Multiple Myeloma

Registration

Date: Friday, December 4, 2020
Time: 3:00 PM - 5:30 PM PST

Virtual Symposium Overview
This live-streamed independent satellite symposium will take place preceding the 2020 American Society of Hematology Annual Meeting
and will be presented on an interactive web platform by 4 renowned experts actively engaged in the care of patients with multiple myeloma. 


Target Audience
The target audience for this activity is community and academic hematologists, medical oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma and are attending the Virtual 2020 ASH Annual Meeting.


Learning Objectives
After participating in this activity, participants should be better able to:

  • Evaluate clinical trial results of frontline treatment options that are available for the treatment of patients with newly diagnosed MM
  • Review maintenance therapy strategies for patients with MM that are eligible to receive this type of therapy
  • Assess treatment approaches and sequencing of therapy for patients with relapsed and/or refractory MM
  • Optimize approaches to manage treatment-related adverse events that may occur during the treatment of patients with MM
  • Discuss clinical trials results that are investigating emerging novel agents in patients with MM

Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


The University of Nebraska Medical Center, Center for Continuing Education, designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Agenda
3:00 PM   Welcome, Introductions, and Pre-session Survey                                        
3:10 PM   Should We be Treating Patients with High-Risk Smoldering MM?                   
3:30 PM   Is There Sufficient Data to Include Antibodies in Frontline Regimens?                  
3:50 PM  Transplant vs No Transplant                  
4:10 PM  Should Antibodies be a Standard Agent Included in Regimens for First Relapse?
4:30 PM 
What Emerging Class of Agents Should Be Used in Relapsed/Refractory MM Upon Approval
                Antibody-Drug Conjugates/Peptide-Drug Conjugates
                Bispecific Antibodies
                CAR T-cells                                                                                
5:00 PM   Panel Discussion
5:15 PM   Audience Q&A
5:25 PM   Post-Session Survey and Closing Remarks
5:30 PM   Program Adjourns

                                    
Chair
Sagar Lonial, MD, FACP

Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia


Faculty
Kenneth Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Program Director
Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Boston, Massachusetts

Pieter Sonneveld, MD

Department Head and Professor of Hematology
Erasmus MC Cancer Institute
University Medical Center Rotterdam
Rotterdam, Holland, Netherlands

Peter Voorhees, MD

Professor of Medicine
Director, Clinical Operations and Outreach for Hematologic Malignancies
Member, Plasma Cell Disorders Program
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Faculty Disclosure Statement
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

Support
This activity is supported by independent educational grants from GlaxoSmithKline,
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Oncopeptides.

Friday Satellite Symposium on Multiple Myeloma, preceding the 62nd ASH Annual Meeting and Exposition

Technical Requirements

This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.